SciELO - Scientific Electronic Library Online

 
vol.33 issue2Analysis of the effect of salt intake on the development of obesityPreliminary evaluation of the effect of Compvit-B on memory and learning processes in patients with SCA2 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Investigaciones Biomédicas

Print version ISSN 0864-0300

Abstract

VELAZQUEZ-PEREZ, Luis et al. Evaluation of the effect of Compvit-B on peripheral neuropathy in patients with mild SCA2. Rev Cubana Invest Bioméd [online]. 2014, vol.33, n.2, pp. 129-139. ISSN 0864-0300.

Introduction: Spinocerebellar ataxia type 2 (SCA2) is a severe neurodegenerative disease which constitutes a serious health problem in Cuba due to its high prevalence and incidence rates and the lack of curative treatments. Objectives: Evaluate the effect and safety of the treatment with high doses of B-complex vitamins (Compvit-B) on peripheral neuropathy in patients with SCA2. Methods: A prospective clinical intervention study was conducted of 20 patients in the mild stage of the disease undergoing a therapeutic protocol consisting in intramuscular injection of Compvit-B for 12 weeks. Patients were administered two ampoules weekly in the first 4 weeks and one from the fifth week onwards. Immediately before and after the treatment patients underwent clinical and electrophysiological examination. Results: Upon completion of the treatment patients showed a significant increase in the amplitude of the sensitive action potentials of the median and sural nerves. In the latter case there was also a decrease in latency and an increase in conduction velocity. Motor nerve conduction parameters were not modified. Somatosensory evoked potentials of the median nerve showed a significant reduction in the latency of Erb's potential. A significant decrease was also found in the frequency of painful muscle contractures in 53% of the cases after treatment. Adverse events were not recorded during the study. Conclusions: The study identifies a new therapeutic option for symptomatic SCA2, and provides new evidence of the pathophysiological bases and clinical management of painful muscle contractures. Broader studies should be conducted with patients and carriers of the mutation, who typically present such manifestations long before developing ataxia.

Keywords : hereditary ataxias; spinocerebellar ataxia type 2; SCA2; peripheral neuropathy; painful muscle contractures; vitamin B; vitamin B complex; Compvit-B.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )